LNP Formulation for mRNA Therapies

Author(s)Pharmaceutical Technology Editors

Polyplus’ LipidBrick IM21.7 is designed to expand the scope of LNP usage in various therapeutic and oncology applications.

Polyplus’ LipidBrick IM21.7 is a novel cationic lipid nanoparticle (LNP) formulation for messenger RNA therapeutic and vaccine development. The formulation is designed to expand the scope of LNP usage in various therapeutic and oncology applications, as well as prophylactic vaccines.

The LipidBrick is designed to overcome current-generation ionizable lipid challenges used in current LNPs by enabling a wider in-vivo biodistribution and decreasing accumulation in the liver. Proof of concept work demonstrated that it successfully modulates the overall charge of LNPs, improving drug efficiency and formulation stability with no additional safety concerns.

Polyplus

Articles in this issue

almost 3 years ago

Article

Using Smart Tools for Smart Development

almost 3 years ago

Article

Frontrunner in Organ-on-a-Chip

almost 3 years ago

Article

Quality Quartets in Risk-Based Qualification

almost 3 years ago

Article

High-Quality Communication Enables High-Quality Drug Products

almost 3 years ago

Article

The Next Challenge in Dissolution–Nanoparticles

almost 3 years ago

Article

Optimizing the Manufacture of Emerging Therapies

almost 3 years ago

Article

Continuous Hot-Melt Extrusion for Poorly Soluble APIs

almost 3 years ago

Article

Springing Forward

almost 3 years ago

Article

On Strike!

almost 3 years ago

Article

Envisioning Digital Pharma Manufacturing

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!